{"filings":[{"id":90800,"accession_number":"0001493152-26-014637","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics sues investor for failing to close $3M financing","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit March 30, 2026 against an institutional investor for breach of the Securities Purchase Agreement.","Investor failed to fund $3,000,000 investment for 12,000,000 shares and 7,000,000 warrants at $0.25 per share.","Company attempted to secure funds without litigation before initiating the suit.","Additional details on the litigation to be provided in a subsequent Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90799,"accession_number":"0001493152-26-014517","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics provides update on itraconazole PK study; plans global patent filing for amorphous formulation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.","Study is the final clinical study before NDA submission to FDA under 505(b)(2) pathway for Gorlin Syndrome BCCNS.","New global patent application planned for proprietary amorphous itraconazole formulation; owned by Inhibitor with no royalty obligations.","Amorphous formulation aims to enhance solubility and absorption vs. crystalline itraconazole to address variable exposure.","Study conducted with Avior Bio in Malaysia; advancing on planned timelines and budget."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100606,"accession_number":"0001493152-26-007821","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.","Investor receives warrants to purchase up to 7,000,000 shares at $0.35/share, exercisable for 3 years.","Proceeds from the private placement will be used for working capital and general corporate purposes.","Shares and warrant shares are subject to a 9-month lock-up agreement that restricts resale.","Closing has not yet occurred; expected within a reasonable time after the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116920,"accession_number":"0001493152-25-019381","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.","Performance-based compensation includes up to 18 million unvested 4-year warrants, vesting upon milestones such as FDA approval or sale of program.","First SOW involves re-analysis of HP2001 clinical study data and preparing FDA meeting request (Type B/C/D).","Board adopted 2025 Equity Incentive Plan reserving 20 million shares; subject to shareholder approval within 12 months.","Consulting agreement continues indefinitely; each project governed by separate SOWs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256282,"accession_number":"0001193125-23-294696","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.","Licensed field of use: prostate cancer, basal cell carcinoma (including BCC nevus syndrome), and lung cancer.","Financial terms include upfront fee, minimum annual royalties, milestone payments, and royalties on net sales.","Company cites this as a critical milestone toward commercializing itraconazole in multiple oncology indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256281,"accession_number":"0001193125-23-258156","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.","Company creates SAB to advise on clinical development; Dr. Elizabeth Billingsley named chairperson.","Consulting agreement with Dermapharm Consulting LLC (Dr. Billingsley) at $600/hour for clinical trial support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273695,"accession_number":"0001193125-23-223590","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Inhibitor Therapeutics expands board to 7, appoints Ronald Osman; bylaws amended","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board increased from 4 to 7 members; Ronald E. Osman appointed as non-independent director.","Amended bylaws require stockholders holding 50% of outstanding shares to bring business at annual meetings.","Bylaw amendment raises vote threshold to amend/repeal bylaws from majority to 66 2/3% of voting stockholders.","Expanded CFO and Secretary roles; removed references to Amended and Restated Equity Holders Agreement.","Mr. Osman is a licensed attorney with over 40 years of experience in False Claims Act litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290712,"accession_number":"0001493152-23-019651","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Michelle Yanez resigns; Michael Jerman appointed to Inhibitor Therapeutics Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle Yanez resigned from the Board effective May 24, 2023, to take a full-time CFO role elsewhere; no disagreement with the company.","Michael Jerman, CPA, appointed as independent director and Chairman of the Audit Committee, effective May 24, 2023.","Jerman brings experience as CFO of private equity-backed companies, former PwC director, and USAF captain; deemed a financial expert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330147,"accession_number":"0001193125-22-308415","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["1.01","1.02","5.01","5.02","9.01"],"status":"ready","headline":"Inhibitor Therapeutics settles derivative and class actions, appoints new CEO and board","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement provides $14.25M cash payment to company from Mayne Pharma's D&O insurance.","Mayne Pharma surrenders all equity and forgives certain debts owed by the company.","Directors and officers resigned; stock options and warrants cancelled.","Francis O'Donnell appointed Executive Chairman and CEO; new board members appointed.","Third Amended Supply and License Agreement terminated; company retains royalty on SUBA-Itraconazole sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347709,"accession_number":"0001193125-22-245701","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhibitor Therapeutics settles derivative/class actions; Mayne to pay $14.25M cash and surrender equity","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Mayne to pay $14.25M cash and surrender all its equity (205M+ common shares, convertible preferred, warrants); Mayne debt of $3M canceled.","Individual defendants Brendan Magrab, Stefan Cross, R. Dana Ono, et al. to retire from board/management; their options/warrants canceled.","Third Amended Supply and License Agreement with Mayne canceled; Company retains royalty on future US SUBA-Itraconazole BCCNS sales.","Company's hedgehog-related patents to Mayne become non-exclusive; Mayne's itraconazole formulation patents licensed to Company are terminated.","Settlement hearing set for November 10, 2022 in Delaware Chancery Court; plaintiffs may seek up to $2M in fees from the cash consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364221,"accession_number":"0001193125-22-167340","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Debra Peattie retires from Inhibitor Therapeutics Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Debra Peattie retired from Board effective June 1, 2022, to focus on other professional opportunities.","Retirement is not based on any disagreement with the company's operations, policies, or practices.","Compensation Committee determined Peattie retired in good standing; vested options may be held for full term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383942,"accession_number":"0001193125-22-011256","cik":1042418,"company_name":"Inhibitor Therapeutics, Inc.","ticker":"INTI","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Inhibitor Therapeutics amends loan with Mayne Pharma: limit to $281K, maturity Dec 2022","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facility limit increased by $50,000 to $281,000; maturity extended to December 31, 2022.","Additional $50,000 available for drawdown from Feb 1 to Mar 31, 2022, in minimum $25,000 increments.","Original $231,000 fully drawn; proceeds used for working capital and deferred employee compensation.","Loan amendment with majority stockholder Mayne Pharma; rest of Loan Agreement unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14668751.363636365,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}